About 1 in 70 people worldwide has celiac disease. That figure alone deserves more attention than it gets. But the more striking number is how many of those people have no idea.
A new systematic review and meta-analysis published in Gastroenterology by Karimzadhagh, Abbaspour, and Shamsi takes a rigorous look at both how common celiac disease is globally and how it actually presents in real patients. The conclusion is a familiar frustration to anyone close to this community: the disease is common, it crosses populations, and the majority of people who have it remain undiagnosed. The reason? Celiac rarely arrives looking the way most people expect.
For those of us raising children with celiac disease, this research puts hard data behind something we have seen firsthand. Getting a diagnosis is difficult — not because the tests are complicated, but because too many clinicians are still waiting for the “classic” symptoms that represent only a fraction of actual cases.
What This Means for You
The diagnosis gap is real and it is large. Estimates from large-scale epidemiological studies consistently find that roughly 80% of people with celiac disease have never been diagnosed. That means the celiac community is far bigger than the treated community — a distinction with serious consequences. Undiagnosed celiac causes ongoing intestinal damage, nutritional deficiencies, elevated cancer risk, and complications ranging from infertility to bone loss. People who do not know they have celiac cannot protect themselves from it.
Part of what drives that gap is a mismatch between expectation and reality. The “classic” celiac presentation — chronic diarrhea, significant weight loss, obvious malabsorption — is now understood to be the minority of cases. Karimzadhagh and colleagues document that celiac is a clinically heterogeneous disease: many patients present with what researchers call “non-classic” symptoms. These include iron-deficiency anemia that does not respond to supplementation, fatigue, joint pain, recurring headaches, neurological symptoms, elevated liver enzymes, and low bone density. Some patients have no gastrointestinal symptoms at all.
For celiac parents, this matters at the diagnostic level and beyond. If the adults around a child — pediatricians, school nurses, coaches — are watching only for the classic picture, non-classic celiac will be missed, sometimes for years. The average diagnostic delay in high-income countries has historically been measured in years, not months. This research gives advocates hard data to push back against that delay.
It also strengthens the argument for systematic screening. If 1 in 70 people has celiac and 4 in 5 of them are undiagnosed, a compelling case exists for proactive testing — particularly among first-degree relatives of diagnosed patients, where prevalence runs far higher than in the general population.
We have covered related ground before in how common celiac disease is and what major prevalence studies have found and in the comprehensive review of celiac epidemiology, pathogenesis, and therapeutic strategies. What this new meta-analysis adds is a fresh global synthesis and an explicit focus on symptom variability — the direct link between clinical heterogeneity and underdiagnosis.
Key Takeaways
- Celiac disease affects approximately 1 in 70 people globally, placing it among the most common autoimmune conditions worldwide.
- Roughly 80% of people with celiac disease have never been diagnosed.
- “Classic” celiac symptoms like chronic diarrhea and weight loss represent the minority of cases.
- Non-classic presentations — anemia, fatigue, bone loss, neurological symptoms, elevated liver enzymes — are frequently misattributed to other conditions.
- Symptom variability is the primary driver of diagnostic delay, which historically stretches years in many countries.
The Science
Want to understand how this actually works? We’ll walk you through the technical details below and define every term. No medical degree required.
How Prevalence Is Measured
A systematic review and meta-analysis combines results from many independent studies to produce more reliable population-level estimates than any single study can. Karimzadhagh, Abbaspour, and Shamsi pooled data from studies across multiple continents, weighting each by sample size and methodological quality to arrive at a global prevalence figure.
Prevalence is typically measured two ways. Seroprevalence refers to the proportion of a population with positive antibody tests — specifically tissue transglutaminase IgA antibodies (tTG-IgA), the standard first-line blood test for celiac. Biopsy-confirmed prevalence requires a positive blood test plus a small intestinal biopsy showing characteristic damage. The gap between seroprevalence and biopsy-confirmed rates reflects different diagnostic thresholds across studies and populations.
Why Clinical Presentation Varies So Widely
Celiac disease is triggered when the immune system responds to gluten — a protein found in wheat, barley, and rye. That immune reaction damages the small intestinal mucosa (the lining of the small intestine), impairing the absorption of nutrients. But the severity and distribution of that damage vary considerably between individuals, which drives the wide symptom range.
Researchers categorize presentations into several types:
- Classic celiac: diarrhea, steatorrhea (fatty stools), significant weight loss, and overt malabsorption — the traditional textbook picture, now understood to be the minority.
- Non-classic (atypical) celiac: symptoms outside the gastrointestinal tract, including iron-deficiency anemia, fatigue, reduced bone mineral density (osteopenia or osteoporosis), peripheral neuropathy (tingling or numbness in the hands and feet), elevated liver enzymes, and reproductive issues including infertility.
- Silent celiac: positive serology and biopsy-confirmed intestinal damage, but no recognized symptoms. The patient does not feel ill despite active disease and ongoing mucosal injury.
- Potential celiac: positive antibody tests but a normal biopsy — these patients may progress to biopsy-confirmed disease over time.
Dermatitis herpetiformis — the skin manifestation of celiac, presenting as an intensely itchy blistering rash typically on elbows, knees, and buttocks — is a distinct diagnosis but is driven by the same immune response and requires the same gluten-free treatment.
The Iceberg Model and the Case for Screening
The “celiac iceberg” is a model researchers have used for decades. The small visible tip represents diagnosed cases. The submerged mass — far larger — represents everyone who has the disease but does not know it. This meta-analysis adds updated global weight to that picture by quantifying both total prevalence and the diagnosed fraction simultaneously.
For first-degree relatives of people with celiac disease — parents, siblings, children of a diagnosed patient — prevalence is estimated at 10–15%, compared to roughly 1–1.4% in the general population. That tenfold difference is the strongest epidemiological argument for targeted screening programs. Several European countries have adopted at-risk screening; the United States has not implemented systematic guidelines.
HLA-DQ2 and HLA-DQ8 are the genetic variants present in nearly all celiac patients — roughly 95% carry HLA-DQ2. But around 30–40% of the general population carries one of these variants without ever developing celiac disease. Genetic risk is necessary but not sufficient; environmental triggers, gut microbiome composition, and timing of gluten exposure all interact with that underlying susceptibility.
For celiac families navigating this reality every day, a study like this one matters beyond the academic. It adds to the evidence that the diagnostic status quo is failing patients. I want my son’s generation of celiac kids to inherit a medical system that recognizes the full picture of this disease — not just the narrow slice that happens to match an outdated textbook.
Related Coverage
- How Common Is Celiac Disease? What the Major Prevalence Studies Tell Us
- Prevalence of Celiac Disease Among Permanent Residents in Northwest China: A Cross-Sectional Survey
- Celiac Disease: A Comprehensive Review of Epidemiology, Pathogenesis, and Therapeutic Strategies
References
Karimzadhagh S, Abbaspour E, Shamsi P. Global Prevalence of Celiac Disease and Clinical Characteristics in the General Population: A Systematic Review and Meta-analysis. Gastroenterology. 2026 Aug 18. PubMed